In Massachusetts, Latest Annual Snapshot Shows a Tale of Two Biopharmas

The job contraction, according to MassBio, reflected pipeline reprioritization by biopharma giants plus contraction by smaller companies, with R&D jobs dropping significantly between Q2 and Q3 of 2025, then starting to bounce back by Q4. The mid-year drop explains last year’s overall 3.9% or 2,563-job decrease in R&D employment statewide, which fell to 62,991 from 65,554 jobs. The post In…